Poly (I:C):Kanamycin (1:1)
Based on 7 publication(s) in Google Scholar
Poly(I:C):Kanamycin (1:1) is a mixture of Poly(I:C) (HY-107202) and Kanamycin (HY-16566). Poly(I:C) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Poly(I:C) can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Poly(I:C) can directly trigger cancer cells to undergo apoptosis. Kanamycin stabilizes Poly(I:C).
For research use only. We do not sell to patients.
- Purity: 48.6%
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Angiogenesis-Related Compound Library
HY-L088
-
Mitochondria-Targeted Compound Library
HY-L089
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cuproptosis Compound Library
HY-L133
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cell Death Library
HY-L162
-
Immunopotentiator Compound Library
HY-L172
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Pattern Recognition Receptors Library
HY-L237
Publications Citing Use of MedChemExpress (MCE) Poly (I:C):Kanamycin (1:1)
More- Adv Funct Mater. 29 August 2022.
- Phytomedicine. 2021 Apr:84:153495. [Abstract]
- Mol Ther Oncolytics. 2022 Aug 25:26:413-428. [Abstract]
- Liver Int. 2022 Dec;42(12):2724-2742. [Abstract]
- Fish Shellfish Immunol. 2026 Apr:171:111162. [Abstract]
- Vet Microbiol. 2025 May:304:110459. [Abstract]
- SSRN. 2021 Apr 26.
Customer Validation & Images
-
RT-PCR
-
WB
-
Others
Biological Activity
|
MDA5 |
RIG-I |
Bcl-2 |
Bax |
IL-17A |
IL-13 |
HSP70 |
Poly (I:C):Kanamycin (0.5-5 μg/mL, 3-24 h) induces a dose- and time-dependent increase in paracellular permeability of immortalized airway epithelial cells[4].
Poly (I:C):Kanamycin (5 μg/mL, 24 h) does not have cytotoxicity to 16HBE14o- cells[4].
Poly (I:C):Kanamycin (5 μg/mL, 6 h) induces disruption of epithelial apical junctional complexes
(AJCs) and tight junctions (TJs) in 16HBE14o- cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:16HBE14o- cells
-
Concentration:5 μg/mL
-
Incubation Time:24 h
-
Result:Did not lead to significant accumulation of LDH in cell-culture medium.
Poly (I:C):Kanamycin (10 μg/mouse, Intraperitoneal injection, single dose) decreases lung tumor growth in mice[3].
Poly (I:C):Kanamycin (1.25 mg/kg, Intraperitoneal injection, single dose) exerts therapeutic effects against cerebral I/R injury through the downregulation of TLR4/MyD88 signaling via TLR3 in MCAO model mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Lung tumor-bearing mice[3]
-
Dosage:10 μg/mouse
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Induced a significant decrease in the growth of pulmonary metastases in tumor-bearing mice. Reduced the amount of lung foci to ≈ 40%. Significantly increased BAL fluid cell numbers. Increased the level of INF-γ and IL-17A, decreased the levels of IL-13. Increased TLR3 expression.
-
Animal Model:Middle cerebral artery occlusion (MCAO) model mice[5]
-
Dosage:1.25 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Reduced focal cerebral I/R injury. Increased the expression of Bcl2, Hsp27, and Hsp70, decreased Bax expression, and reduced cellular degeneration and apoptosis. Protected against cerebral ischemia and conferred protection against cerebral I/R injury through the downregulation of TLR4 signaling via TLR3.
Chemical Information
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Poly(I:C):Kanamycin(1:1)]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
-
Phytomedicine
Si-Ni-San ameliorates chronic colitis by modulating type I interferons-mediated inflammation. [Abstract]2021 Apr:84:153495. PMID: 33611210 -
Mol Ther Oncolytics
TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I. [Abstract]2022 Aug 25:26:413-428. PMID: 36159777
Poly (I:C):Kanamycin (1:1) purchased from MedChemExpress. Usage Cited in: Mol Ther Oncolytics. 2022 Aug 25:26:413-428. [Abstract]
Dual-luciferase reporter assay of PPAS (20 ng/ml for 24 h) on CCAR1 promoter in U251MG and 293T cells was performed.
-
Liver Int
Human poliovirus receptor contributes to biliary atresia pathogenesis by exacerbating natural-killer-cell-mediated bile duct injury. [Abstract]2022 Dec;42(12):2724-2742. PMID: 36251580 -
Fish Shellfish Immunol
CiLSM14Aa acts as a cytosolic dsRNA sensor to activate antiviral immunity against GCRV-II. [Abstract]2026 Apr:171:111162. PMID: 41611139 -
Vet Microbiol
Serum amyloid P component suppresses porcine epidemic diarrhea virus replication through TLR4-mediated IFN-β signaling pathway. [Abstract]2025 May:304:110459. PMID: 40080977
Poly (I:C):Kanamycin (1:1) purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2025 May:304:110459. [Abstract]
HEK-293T cells were transfected with pGFP-C1-SAP or GFP-C1 and stimulated with or without Poly (I:C):Kanamycin (1:1) and SeV, respectively. After cell collection, the expression levels of relevant factors were detected by RT-qPCR.
Poly (I:C):Kanamycin (1:1) purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2025 May:304:110459. [Abstract]
HEK-293T cells were transfected with pGFP-C1-SAP or GFP-C1 and stimulated with or without Poly (I:C):Kanamycin (1:1) and SeV, respectively. After cell collection, the expression levels of relevant factors were detected by Western blotting.
-
Solvent & Solubility
H2O : 50 mg/mL (Need ultrasonic)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 20 mg/mL; Clear solution; Need ultrasonic and warming and heat to 60°C
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223. [Content Brief]
[2]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101. [Content Brief]
[3]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364. [Content Brief]
[4]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11. [Content Brief]
[5]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz